Healthcare
Essex Woodlands promotes Barry, Yang in Shanghai
Silicon Valley-based healthcare investor Essex Woodlands has promoted David Yang and Scott Barry, who run its Shanghai office, to managing director. The promotions, two of five made by the company globally, came into effect on January 1.
Carlyle exits Japan's Qualicaps to Mitsubishi Chemical
The Carlyle Group has exited its holding in Qualicaps, a supplier of pharma-grade capsules, to Mitsubishi Chemical Holdings for JPY55.8billion ($639 million).
ShangPhama board agrees to TPG-backed buyout
ShangPharma Corporation, a Chinese pharmaceutical and biotech research outsourcing firm listed on the New York Stock Exchange, has agreed to management buyout by Michael Hui, the firm’s chairman and CEO, and TPG Capital. The transaction values the company...
Wilson Sonsini opens Beijing office
Venture capital-focused law firm Wilson Sonsini has opened an office in Beijing, enlarging a Greater China footprint that already takes in Shanghai and Hong Kong. The office is led by Kefei Li, a partner with the firm. He reports to Weiheng Chen, the...
Healthcare-focused Essex Woodlands opens Shanghai office
Essex Woodlands, the Silicon Valley-based healthcare investor, has opened an office in Shanghai as it looks to deepen its exposure to one of China’s fastest-growing sectors. David Yang and Scott Barry, both managing directors with the firm, will run operations...
Olympus-backed DM Healthcare targets IPO by 2015
Olympus Capital-backed DM Healthcare, a Dubai-based healthcare services provider which gets a majority of its business in the Middle East, aims to go public by 2015.
Sutherland Global Services to acquire Apollo's PE-backed BPO arm
Sutherland Global Services, a US-based business process and technology management services, has signed a definitive agreement to acquire Apollo Health Street (AHS), Apollo Hospitals’ healthcare business process outsourcing (BPO) arm. The company is part-owned...
Norwest Venture Partners invests $6m in Indian IT firm Attune
Norwest Venture Partners has invested INR326 million ($6 million) in cloud-based IT product company Attune.
Piramal's IndiaVenture Adviors to raise $185m fund
IndiaVenture Advisors, the PE arm of Indian pharmaceuticals company Piramal Enterprises, plans to raise a fund of up to INR10 billion ($185 million) that will target healthcare and education.
Australia's Harbart Private Equity buys Cardioscan
Harbert Australia Private Equity has bought an 85% stake in Melbourne-based cardiac testing service provider Cardioscan.
Abraaj exits Thai hospital with 3x return
Of the 19 million tourists who visited Thailand in 2011, an estimated 500,000 traveled specifically for medical care. Although medical tourism only accounts for 0.4% of national GDP, the industry is growing at an annual rate of 16% and is expected to...
Aureos, GSB exit Thai hospital interest to Malaysia's KPJ
Aureos Capital and GSB Private Funds – a vehicle set up by Thailand’s Government Savings Bank and managed by ING – have agreed to exit their holdings in Vejthani Hospital to KPJ Healthcare, a hospital chain with assets in Malaysia and Indonesia for THB605.6...
IFC invests $25m in Quadria Capital's healthcare fund
International Finance Corporation (IFC), the private investment arm of the World Bank, is planning to invest $25 million into Quadria Capital’s $300 million private equity fund. The vehicle focuses primarily on healthcare sector assets across South and...
TriReme Medical closes $18m round led by Luminor Capital
Singapore-based Luminor Capital has a led a $18 million financing round in TriReme Medica, a medical device company based in Pleasanton, California and Singapore. Major existing investors and new Asian investors also participated.
IncuCapital backs genetic diagnostic start-up
IncuCapital, an incubation and early-stage investment firm, has invested an undisclosed amount in Mumbai-based genetic diagnostics and research start-up Navigene Genetic Science. IncuCapital’s Surojit Nandy will join the Navigene board.
Matrix India invests in Mewar Orthopaedic
Matrix Partners India has taken a minority stake in specialty healthcare provider Mewar Orthopaedic Hospitals for an undisclosed amount as part of a Series A round of investment.
VCs channel $25m into China's Innovent Biologics
Innovent Biologics, a China-based manufacturer of monoclonal antibodies, has raised $25 million in Series B financing from Lilly Asia Ventures, the VC arm of global pharmaceutical company Eli Lilly, and existing investors Fidelity Biosciences and Fidelity...
Sequoia India invests $6.1m in pathology chain
Sequioa Capital has invested INR400million ($7.5 million) in Indian pathology services provider Suburban Diagnositic for a 30% stake.
Fidelity commits $74m to India's Trivitron Healthcare
Fidelity Growth Partners India has invested INR4 billion ($74.4 million) in medical technology firm Trivitron Healthcare. The funding will be used to make lateral acquisitions in Europe and the US as well as to improve the Chennai-headquartered company’s...
GE Capital to invest in Biocon's research services subsidiary
GE capital, the private equity arm of General Electric, has agreed to invest INR1.25 billion ($23 million) for a 7.69% stake in Syngene, a subsidiary of India’s Biocon.
Shanghai VC firm launches JV with MicuRx Pharma
Shanghai Zhangjiang Biomedical Industry Venture Capital has formed a joint venture with MicuRx Pharma, a Sino-US bio-pharmaceutical company, to support the development and commercialization of antibiotic MRX-I for the Chinese market.
J-Star sees 3x return on consolidation play
Fierce competition among the middle-men in Japan’s pharmaceutical industry has created a healthy environment for private equity firms looking to consolidate a fragmented sector. Last week J-Star exited Apo Plus Station (APS) after a two-year holding...
Japan's government to set up $500m VC drug fund
The Japanese government plans to set up a public-private fund to support research into drugs targeting cancer, hepatitis, diabetes and other difficult-to-treat diseases.
IFC to anchor Fosun Pharma's Hong Kong IPO
International Finance Corporation (IFC), the investment arm of the World Bank, is expected to anchor Shanghai Fosun Pharmaceutical’s Hong Kong IPO alongside Prudential Financial. The total cornerstone commitment is $75 million out of a targeted $600 million...